116 related articles for article (PubMed ID: 12935928)
21. Upregulated genes at 2q24 gains as candidate oncogenes in hepatoblastomas.
Rodrigues TC; Fidalgo F; da Costa CM; Ferreira EN; da Cunha IW; Carraro DM; Krepischi AC; Rosenberg C
Future Oncol; 2014 Dec; 10(15):2449-57. PubMed ID: 25525853
[TBL] [Abstract][Full Text] [Related]
22. Expression of genes involved with cell cycle control, cell growth and chromatin modification are altered in hepatoblastomas.
Gray SG; Hartmann W; Eriksson T; Ekstrom C; Holm S; Kytola S; von Schweinitz D; Pietsch T; Larsson C; Kogner P; Sandstedt B; Ekstrom TJ
Int J Mol Med; 2000 Aug; 6(2):161-9. PubMed ID: 10891560
[TBL] [Abstract][Full Text] [Related]
23. Loss of imprinting in hepatoblastoma.
Rainier S; Dobry CJ; Feinberg AP
Cancer Res; 1995 May; 55(9):1836-8. PubMed ID: 7728748
[TBL] [Abstract][Full Text] [Related]
24. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: cytogenetic and comparative genomic hybridization analysis.
Kumon K; Kobayashi H; Namiki T; Tsunematsu Y; Miyauchi J; Kikuta A; Horikoshi Y; Komada Y; Hatae Y; Eguchi H; Kaneko Y
Jpn J Cancer Res; 2001 Aug; 92(8):854-62. PubMed ID: 11509117
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic analysis of hepatoblastoma: hypothesis of cytogenetic evolution in such tumors and results of a multicentric study.
Sainati L; Leszl A; Stella M; Montaldi A; Perilongo G; Rugge M; Bolcato S; Iolascon A; Basso G
Cancer Genet Cytogenet; 1998 Jul; 104(1):39-44. PubMed ID: 9648556
[TBL] [Abstract][Full Text] [Related]
26. Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma.
Albrecht S; Hartmann W; Houshdaran F; Koch A; Gärtner B; Prawitt D; Zabel BU; Russo P; Von Schweinitz D; Pietsch T
Int J Cancer; 2004 Sep; 111(4):627-32. PubMed ID: 15239143
[TBL] [Abstract][Full Text] [Related]
27. Activated NOTCH2 is overexpressed in hepatoblastomas: an immunohistochemical study.
Litten JB; Chen TT; Schultz R; Herman K; Comstock J; Schiffman J; Tomlinson GE; Rakheja D
Pediatr Dev Pathol; 2011; 14(5):378-83. PubMed ID: 21639801
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma.
Pietsch T; Fonatsch C; Albrecht S; Maschek H; Wolf HK; von Schweinitz D
Lab Invest; 1996 Apr; 74(4):809-18. PubMed ID: 8606490
[TBL] [Abstract][Full Text] [Related]
29. Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma.
Liu BH; Zhang BB; Liu XQ; Zheng S; Dong KR; Dong R
Cell Physiol Biochem; 2018; 45(2):706-719. PubMed ID: 29414822
[TBL] [Abstract][Full Text] [Related]
30. Promoter-specific methylation and expression alterations of igf2 and h19 are involved in human hepatoblastoma.
Li X; Kogner P; Sandstedt B; Haas OA; Ekström TJ
Int J Cancer; 1998 Jan; 75(2):176-80. PubMed ID: 9462704
[TBL] [Abstract][Full Text] [Related]
31. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
32. Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma.
Montagna M; Menin C; Chieco-Bianchi L; D'Andrea E
J Cancer Res Clin Oncol; 1994; 120(12):732-6. PubMed ID: 7798299
[TBL] [Abstract][Full Text] [Related]
33. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma.
Eriksson T; Frisk T; Gray SG; von Schweinitz D; Pietsch T; Larsson C; Sandstedt B; Ekström TJ
Exp Cell Res; 2001 Oct; 270(1):88-95. PubMed ID: 11597130
[TBL] [Abstract][Full Text] [Related]
34. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
35. H19 and IGF-2 allele-specific expression in hepatoblastoma.
Ross JA; Radloff GA; Davies SM
Br J Cancer; 2000 Feb; 82(4):753-6. PubMed ID: 10732739
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas.
Luo JH; Ren B; Keryanov S; Tseng GC; Rao UN; Monga SP; Strom S; Demetris AJ; Nalesnik M; Yu YP; Ranganathan S; Michalopoulos GK
Hepatology; 2006 Oct; 44(4):1012-24. PubMed ID: 17006932
[TBL] [Abstract][Full Text] [Related]
37. Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas.
von Horn H; Tally M; Hall K; Eriksson T; Ekström TJ; Gray SG
Cancer Lett; 2001 Jan; 162(2):253-60. PubMed ID: 11146233
[TBL] [Abstract][Full Text] [Related]
38. Maintenance of genomic imprinting at the IGF2 locus in hepatoblastoma.
Davies SM
Cancer Res; 1993 Oct; 53(20):4781-3. PubMed ID: 8402661
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity on chromosome 1 in human hepatoblastoma.
Kraus JA; Albrecht S; Wiestler OD; von Schweinitz D; Pietsch T
Int J Cancer; 1996 Aug; 67(4):467-71. PubMed ID: 8759602
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of members of the IGF-axis in hepatoblastomas.
Gray SG; Eriksson T; Ekström C; Holm S; von Schweinitz D; Kogner P; Sandstedt B; Pietsch T; Ekström TJ
Br J Cancer; 2000 May; 82(9):1561-7. PubMed ID: 10789725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
